AGIO
Agios Pharmaceuticals, Inc.
Price Chart
Latest Quote
$28.16
Current Price| Previous Close | $27.44 |
| Open | $27.18 |
| Day High | $28.69 |
| Day Low | $26.53 |
| Volume | 827,507 |
Stock Information
| Shares Outstanding | 58.31M |
| Total Debt | $44.52M |
| Cash Equivalents | $952.86M |
| Revenue | $44.79M |
| Net Income | $-401.26M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.64B |
| EPS (TTM) | $-7.01 |
| Exchange | NMS |
📊 Custom Metrics & Score
Score: 19/42| Debt to Equity | 0.04 |
| Debt to Earnings | 1.76 |
| Current Ratio | 11.90 |
| Quick Ratio | 11.06 |
| Profit Margin | 1845.92% |
| Return on Equity | 43.72% |
| Avg FCF Growth | -1.30% |
| FCF Yield | -23.84% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $28.16 | 851,472 |
| 2026-01-30 | $27.44 | 553,300 |
| 2026-01-29 | $27.61 | 827,500 |
| 2026-01-28 | $28.31 | 1,187,400 |
| 2026-01-27 | $28.67 | 913,600 |
| 2026-01-26 | $28.83 | 1,142,700 |
| 2026-01-23 | $28.54 | 993,400 |
| 2026-01-22 | $28.66 | 792,000 |
| 2026-01-21 | $27.17 | 1,133,100 |
| 2026-01-20 | $26.68 | 897,700 |
| 2026-01-16 | $27.19 | 975,800 |
| 2026-01-15 | $27.80 | 805,500 |
| 2026-01-14 | $28.73 | 769,200 |
| 2026-01-13 | $27.80 | 659,000 |
| 2026-01-12 | $28.32 | 904,400 |
| 2026-01-09 | $28.41 | 1,171,300 |
| 2026-01-08 | $28.16 | 1,095,500 |
| 2026-01-07 | $28.54 | 1,299,600 |
| 2026-01-06 | $27.47 | 927,700 |
| 2026-01-05 | $27.45 | 1,068,000 |
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
📰 Latest News
Is Agios Pharmaceuticals (AGIO) Offering A Compelling Entry Point After Recent Share Price Swings
Simply Wall St. • 2026-01-20T17:11:29Z
Agios Pharmaceuticals, Inc. (AGIO): A Bull Case Theory
Insider Monkey • 2026-01-19T22:19:04Z
Agios Pharmaceuticals Touts 2026 Growth Plan at JPM: Acvezmi Launch, SCD Data, Expense Discipline
MarketBeat • 2026-01-14T18:16:31Z
Agios Pharmaceuticals outlines 2026 strategic priorities
TipRanks • 2026-01-13T12:27:08Z
What Catalysts Are Rewriting The Story For Agios Pharmaceuticals (AGIO)?
Simply Wall St. • 2026-01-08T13:15:46Z
Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains?
Zacks • 2025-12-26T13:42:00Z
Agios (AGIO) Gets 18.6% Boost from Aqvesme OK
Insider Monkey • 2025-12-25T15:39:13Z
Agios Pharmaceuticals price target raised to $34 from $32 at BofA
TipRanks • 2025-12-25T11:05:33Z
Here's Why Shares in Agios Pharmaceuticals Popped Today
Motley Fool • 2025-12-24T17:23:24Z
Top Midday Stories: Apple's Cook Buys $3 Million in Nike Stock; OpenAI Explores Ads in ChatGPT; Sanofi-Dynavax $2.2 Billion Deal
MT Newswires • 2025-12-24T16:51:09ZIncome Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $4,165,000 | $2,881,000 | $1,704,000 | $0 |
| Cost Of Revenue | $4,165,000 | $2,881,000 | $1,704,000 | $0 |
| Total Revenue | $36,498,000 | $26,823,000 | $14,240,000 | $0 |
| Operating Revenue | $36,498,000 | $26,823,000 | $14,240,000 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $462,235,000 | $418,310,000 | $403,287,000 | $378,418,000 |
| Other Income Expense | $1,095,623,000 | $6,055,000 | $144,453,000 | $21,072,000 |
| Other Non Operating Income Expenses | $6,487,000 | $6,055,000 | $6,749,000 | $14,433,000 |
| Net Non Operating Interest Income Expense | $48,083,000 | $33,344,000 | $12,793,000 | $836,000 |
| Operating Expense | $458,070,000 | $415,429,000 | $401,583,000 | $378,418,000 |
| Total Other Finance Cost | - | - | $-12,793,000 | $-836,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $673,725,000 | $-352,088,000 | $-231,801,000 | $-356,510,000 |
| Net Interest Income | $48,083,000 | $33,344,000 | $12,793,000 | $836,000 |
| Interest Income | $48,083,000 | $33,344,000 | $12,793,000 | $836,000 |
| Normalized Income | $-347,884,568 | $-352,088,000 | $-369,505,000 | $-363,149,000 |
| Net Income From Continuing And Discontinued Operation | $673,725,000 | $-352,088,000 | $-231,801,000 | $1,604,715,000 |
| Total Operating Income As Reported | $-425,737,000 | $-391,487,000 | $-389,047,000 | $-378,418,000 |
| Net Income Common Stockholders | $673,725,000 | $-352,088,000 | $-231,801,000 | $1,604,715,000 |
| Net Income | $673,725,000 | $-352,088,000 | $-231,801,000 | $1,604,715,000 |
| Net Income Including Noncontrolling Interests | $673,725,000 | $-352,088,000 | $-231,801,000 | $1,604,715,000 |
| Net Income Continuous Operations | $673,725,000 | $-352,088,000 | $-231,801,000 | $-356,510,000 |
| Pretax Income | $717,969,000 | $-352,088,000 | $-231,801,000 | $-356,510,000 |
| Special Income Charges | $1,089,136,000 | $0 | $137,704,000 | $6,639,000 |
| Interest Income Non Operating | $48,083,000 | $33,344,000 | $12,793,000 | $836,000 |
| Operating Income | $-425,737,000 | $-391,487,000 | $-389,047,000 | $-378,418,000 |
| Gross Profit | $32,333,000 | $23,942,000 | $12,536,000 | $0 |
| Net Income Discontinuous Operations | - | $0 | $0 | $1,961,225,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $11.64 | $-6.33 | $-4.23 | $26.55 |
| Basic EPS | $11.86 | $-6.33 | $-4.23 | $26.55 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $67,526,432 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-1,509,220,000 | $-384,864,000 | $-518,187,000 | $-375,817,000 |
| Total Unusual Items | $1,089,136,000 | $0 | $137,704,000 | $6,639,000 |
| Total Unusual Items Excluding Goodwill | $1,089,136,000 | $0 | $137,704,000 | $6,639,000 |
| Reconciled Depreciation | $5,653,000 | $6,623,000 | $8,564,000 | $9,240,000 |
| EBITDA (Bullshit earnings) | $-420,084,000 | $-384,864,000 | $-380,483,000 | $-369,178,000 |
| EBIT | $-425,737,000 | $-391,487,000 | $-389,047,000 | $-378,418,000 |
| Diluted Average Shares | $57,889,255 | $55,651,487 | $54,789,435 | $60,447,346 |
| Basic Average Shares | $56,807,415 | $55,651,487 | $54,789,435 | $60,447,346 |
| Diluted NI Availto Com Stockholders | $673,725,000 | $-352,088,000 | $-231,801,000 | $1,604,715,000 |
| Tax Provision | $44,244,000 | $0 | $0 | - |
| Gain On Sale Of Business | $1,089,136,000 | $0 | $137,704,000 | $6,639,000 |
| Research And Development | $301,286,000 | $295,526,000 | $279,910,000 | $256,973,000 |
| Selling General And Administration | $156,784,000 | $119,903,000 | $121,673,000 | $121,445,000 |
| Restructuring And Mergern Acquisition | - | - | $-127,853,000 | $0 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $1,540,956,000 | $811,019,000 | $1,100,814,000 | $1,291,975,000 |
| Total Assets | $1,663,199,000 | $937,118,000 | $1,238,718,000 | $1,437,736,000 |
| Total Non Current Assets | $697,599,000 | $103,283,000 | $405,946,000 | $373,505,000 |
| Other Non Current Assets | $4,724,000 | $4,057,000 | $3,956,000 | $2,900,000 |
| Investmentin Financial Assets | $638,321,000 | $29,435,000 | $313,874,000 | $266,375,000 |
| Current Assets | $965,600,000 | $833,835,000 | $832,772,000 | $1,064,231,000 |
| Other Current Assets | $40,165,000 | $35,021,000 | $38,955,000 | $39,835,000 |
| Inventory | $27,616,000 | $19,076,000 | $8,492,000 | $0 |
| Receivables | $4,109,000 | $2,810,000 | $2,206,000 | $4,378,000 |
| Accounts Receivable | $4,109,000 | $2,810,000 | $2,206,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $893,710,000 | $776,928,000 | $783,119,000 | $1,020,018,000 |
| Cash And Cash Equivalents | $76,247,000 | $88,205,000 | $139,259,000 | $203,126,000 |
| Assets Held For Sale Current | - | - | - | $0 |
| Prepaid Assets | - | - | - | $39,835,000 |
| Other Receivables | - | - | - | $4,378,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $56,988,000 | $71,996,000 | $85,659,000 | $97,094,000 |
| Long Term Debt And Capital Lease Obligation | $40,207,000 | $56,988,000 | $71,996,000 | $85,935,000 |
| Current Debt And Capital Lease Obligation | $16,781,000 | $15,008,000 | $13,663,000 | $11,159,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $122,243,000 | $126,099,000 | $137,904,000 | $145,761,000 |
| Total Non Current Liabilities Net Minority Interest | $41,087,000 | $58,144,000 | $75,275,000 | $85,935,000 |
| Other Non Current Liabilities | $880,000 | $1,156,000 | $3,279,000 | - |
| Current Liabilities | $81,156,000 | $67,955,000 | $62,629,000 | $59,826,000 |
| Payables And Accrued Expenses | $34,440,000 | $29,715,000 | $30,861,000 | $28,849,000 |
| Payables | $17,514,000 | $9,780,000 | $18,616,000 | $16,700,000 |
| Total Tax Payable | $871,000 | $0 | - | - |
| Income Tax Payable | $871,000 | $0 | - | - |
| Accounts Payable | $16,643,000 | $9,780,000 | $18,616,000 | $16,700,000 |
| Liabilities Heldfor Sale Non Current | - | - | - | $0 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $1,540,956,000 | $811,019,000 | $1,100,814,000 | $1,291,975,000 |
| Total Equity Gross Minority Interest | $1,540,956,000 | $811,019,000 | $1,100,814,000 | $1,291,975,000 |
| Stockholders Equity | $1,540,956,000 | $811,019,000 | $1,100,814,000 | $1,291,975,000 |
| Gains Losses Not Affecting Retained Earnings | $-1,518,000 | $-441,000 | $-12,535,000 | $-1,198,000 |
| Other Equity Adjustments | $-1,518,000 | $-441,000 | $-12,535,000 | $-1,198,000 |
| Retained Earnings | $-148,924,000 | $-822,649,000 | $-470,561,000 | $-238,760,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Treasury Shares Number | $16,216,411 | $16,216,411 | $16,216,411 | $16,216,411 |
| Ordinary Shares Number | $57,156,285 | $55,945,078 | $55,039,707 | $54,334,220 |
| Share Issued | $73,372,696 | $72,161,489 | $71,256,118 | $70,550,631 |
| Tangible Book Value | $1,540,956,000 | $811,019,000 | $1,100,814,000 | $1,291,975,000 |
| Invested Capital | $1,540,956,000 | $811,019,000 | $1,100,814,000 | $1,291,975,000 |
| Working Capital | $884,444,000 | $765,880,000 | $770,143,000 | $1,004,405,000 |
| Capital Lease Obligations | $56,988,000 | $71,996,000 | $85,659,000 | $97,094,000 |
| Total Capitalization | $1,540,956,000 | $811,019,000 | $1,100,814,000 | $1,291,975,000 |
| Treasury Stock | $802,486,000 | $802,486,000 | $802,486,000 | $802,486,000 |
| Additional Paid In Capital | $2,493,811,000 | $2,436,523,000 | $2,386,325,000 | $2,334,348,000 |
| Capital Stock | $73,000 | $72,000 | $71,000 | $71,000 |
| Common Stock | $73,000 | $72,000 | $71,000 | $71,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $40,207,000 | $56,988,000 | $71,996,000 | $85,935,000 |
| Current Capital Lease Obligation | $16,781,000 | $15,008,000 | $13,663,000 | $11,159,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $29,935,000 | $23,232,000 | $18,105,000 | $19,818,000 |
| Current Accrued Expenses | $16,926,000 | $19,935,000 | $12,245,000 | $12,149,000 |
| Investments And Advances | $638,321,000 | $29,435,000 | $313,874,000 | $266,375,000 |
| Available For Sale Securities | $638,321,000 | $29,435,000 | $313,874,000 | $266,375,000 |
| Net PPE | $54,554,000 | $69,791,000 | $88,116,000 | $104,230,000 |
| Accumulated Depreciation | $-56,497,000 | $-52,229,000 | $-50,070,000 | $-44,974,000 |
| Gross PPE | $111,051,000 | $122,020,000 | $138,186,000 | $149,204,000 |
| Leases | $37,519,000 | $37,277,000 | $37,277,000 | $32,726,000 |
| Construction In Progress | $897,000 | $608,000 | $657,000 | $7,368,000 |
| Other Properties | $17,529,000 | $17,433,000 | $23,182,000 | $22,348,000 |
| Machinery Furniture Equipment | $12,227,000 | $12,293,000 | $11,941,000 | $11,638,000 |
| Buildings And Improvements | $42,879,000 | $54,409,000 | $65,129,000 | $75,124,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $3,018,000 | $1,457,000 | $942,000 | $0 |
| Work In Process | $24,509,000 | $17,568,000 | $7,550,000 | $0 |
| Raw Materials | $89,000 | $51,000 | $0 | $0 |
| Other Short Term Investments | $817,463,000 | $688,723,000 | $643,860,000 | $816,892,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-391,526,000 | $-314,561,000 | $-314,359,000 | $-413,061,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-389,841,000 | $-296,062,000 | $-309,478,000 | $-407,320,000 |
| Cash Flow From Continuing Operating Activities | $-389,841,000 | $-296,062,000 | $-309,478,000 | $-314,086,000 |
| Operating Gains Losses | $-200,206,000 | $525,000 | $-48,000 | $12,000 |
| Cash From Discontinued Operating Activities | - | $0 | $0 | $-93,234,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-1,685,000 | $-18,499,000 | $-4,881,000 | $-5,741,000 |
| Investing Cash Flow | $363,441,000 | $239,575,000 | $243,261,000 | $1,248,778,000 |
| Cash Flow From Continuing Investing Activities | $363,441,000 | $239,575,000 | $243,261,000 | $-554,158,000 |
| Cash From Discontinued Investing Activities | - | $0 | $0 | $1,802,936,000 |
| Net Other Investing Changes | - | - | $131,784,000 | - |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Financing Cash Flow | $14,442,000 | $5,433,000 | $2,350,000 | $-765,768,000 |
| Cash Flow From Continuing Financing Activities | $14,442,000 | $5,433,000 | $2,350,000 | $-765,768,000 |
| Repurchase Of Capital Stock | - | $0 | $0 | $-802,486,000 |
| Net Common Stock Issuance | - | $0 | $0 | $-802,486,000 |
| Cash From Discontinued Financing Activities | - | - | $0 | $0 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $0 | $0 | $-331,000 | $-578,000 |
| Income Tax Paid Supplemental Data | $43,150,000 | $1,569,000 | $0 | $16,078,000 |
| End Cash Position | $76,247,000 | $88,205,000 | $139,259,000 | $203,126,000 |
| Beginning Cash Position | $88,205,000 | $139,259,000 | $203,126,000 | $127,436,000 |
| Changes In Cash | $-11,958,000 | $-51,054,000 | $-63,867,000 | $75,690,000 |
| Proceeds From Stock Option Exercised | $14,442,000 | $5,433,000 | $2,681,000 | $37,296,000 |
| Net Issuance Payments Of Debt | $0 | $0 | $-331,000 | $-578,000 |
| Net Long Term Debt Issuance | $0 | $0 | $-331,000 | $-578,000 |
| Long Term Debt Payments | $0 | $0 | $-331,000 | $-578,000 |
| Net Investment Purchase And Sale | $-724,050,000 | $256,749,000 | $115,394,000 | $-548,417,000 |
| Sale Of Investment | $818,383,000 | $674,679,000 | $1,146,175,000 | $829,804,000 |
| Purchase Of Investment | $-1,542,433,000 | $-417,930,000 | $-1,030,781,000 | $-1,378,221,000 |
| Net Business Purchase And Sale | $1,089,136,000 | $0 | $131,784,000 | $0 |
| Sale Of Business | $1,089,136,000 | $0 | $131,784,000 | $0 |
| Net Intangibles Purchase And Sale | $0 | $-17,500,000 | $0 | $0 |
| Purchase Of Intangibles | $0 | $-17,500,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-1,645,000 | $326,000 | $-3,917,000 | $-5,741,000 |
| Sale Of PPE | $40,000 | $1,325,000 | $964,000 | $0 |
| Purchase Of PPE | $-1,685,000 | $-999,000 | $-4,881,000 | $-5,741,000 |
| Change In Working Capital | $-19,768,000 | $-19,057,000 | $-16,433,000 | $-36,822,000 |
| Change In Other Current Liabilities | $-15,284,000 | $-15,786,000 | $-7,825,000 | $-7,527,000 |
| Change In Payables And Accrued Expense | $11,166,000 | $4,084,000 | $1,819,000 | $1,929,000 |
| Change In Accrued Expense | $3,694,000 | $12,817,000 | $-1,617,000 | $66,000 |
| Change In Payable | $7,472,000 | $-8,733,000 | $3,436,000 | $1,863,000 |
| Change In Account Payable | $6,601,000 | $-8,733,000 | $3,436,000 | $1,863,000 |
| Change In Tax Payable | $871,000 | $0 | $0 | - |
| Change In Income Tax Payable | $871,000 | $0 | $0 | - |
| Change In Prepaid Assets | $-5,811,000 | $3,833,000 | $-176,000 | $-26,846,000 |
| Change In Inventory | $-8,540,000 | $-10,584,000 | $-8,492,000 | $0 |
| Change In Receivables | $-1,299,000 | $-604,000 | $-1,759,000 | $-4,378,000 |
| Changes In Account Receivables | $-1,299,000 | $-604,000 | $-2,206,000 | $0 |
| Other Non Cash Items | $-877,606,000 | $28,220,000 | $-117,858,000 | $9,537,000 |
| Stock Based Compensation | $42,847,000 | $44,766,000 | $49,296,000 | $53,508,000 |
| Amortization Of Securities | $-14,486,000 | $-5,051,000 | $-1,198,000 | $6,949,000 |
| Depreciation Amortization Depletion | $5,653,000 | $6,623,000 | $8,564,000 | $9,240,000 |
| Depreciation And Amortization | $5,653,000 | $6,623,000 | $8,564,000 | $9,240,000 |
| Gain Loss On Investment Securities | $-167,000 | $-28,000 | - | - |
| Gain Loss On Sale Of PPE | $-39,000 | $553,000 | $-48,000 | $12,000 |
| Gain Loss On Sale Of Business | $-200,000,000 | $0 | $0 | - |
| Net Income From Continuing Operations | $673,725,000 | $-352,088,000 | $-231,801,000 | $-356,510,000 |
| Common Stock Payments | - | $0 | $0 | $-802,486,000 |